Categories
Archives
- 2026
- 2025
- 2024
- 2023
Feb
27
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
Feb
25
Shining a Light on Resilience: Honoring Black History Month and Raising Awareness for Epilepsy
Feb
12
Providing U.S. Policy Actions on Rare Disease
Feb
03
Rare Disease Day 2025: Elevating the Lives of the Under-served and Under-represented
Jan
31
Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape
Jan
16
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
Dec
18
Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions
Dec
06
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
Nov
26
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
